Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04566393
Title Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Recruitment Available
Gender both
Phase Expanded access
Variant Requirements Yes
Sponsors xCures
Indications

Advanced Solid Tumor

Therapies

Ulixertinib

Age Groups: child | adult | senior
Covered Countries USA

Additional content available in CKB BOOST